

Ivy Foundation and Stanford University, Evaluation of Response to Anti-Angiogenesis Therapy in Recurrent

New imaging agent for PET (^{18}F FPPRGD₂) was compared to standard of care FDG PET and MRI for detection of brain tumor recurrence and for early evaluation of response to treatment

PRINCIPAL INVESTIGATORS:



Sam Gambhir, PH.D.

Stanford University



Andrei Iagaru, PH.D.

Stanford University

OBJECTIVES:

- Evaluate if the new PET imaging agent can be used to scan patients with brain tumors.
- Compare the new PET agent with the standard of care FDG PET and MRI.

PROGRESS REPORT:

- The new PET imaging agent produced no side effects or toxicity in 20 cancer patients (8 with brain cancers) and 5 volunteers not diagnosed with brain cancer.
- The new PET imaging agent detected all recurring brain tumors, sometimes even before they could be seen on MRI.
- Two patients have been scanned with the new PET agent before and after Avastin treatment and as early as 1 week there were changes in the way the images looked like, suggesting that it may help evaluate response to treatment.

www.IvyFoundation.org